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Abstract
Background: Huntington’s disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the
Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as
well as aggregate formation of mutant Htt. Effective treatments for HD are yet to be developed.
Methodology/Principal Findings: Here, we report a novel dual-function compound, N
6-(4-hydroxybenzyl)adenine riboside
(designated T1-11) which activates the A2AR and a major adenosine transporter (ENT1). T1-11 was originally isolated from a
Chinese medicinal herb. Molecular modeling analyses showed that T1-11 binds to the adenosine pockets of the A2AR and
ENT1. Introduction of T1-11 into the striatum significantly enhanced the level of striatal adenosine as determined by a
microdialysis technique, demonstrating that T1-11 inhibited adenosine uptake in vivo. A single intraperitoneal injection of
T1-11 in wildtype mice, but not in A2AR knockout mice, increased cAMP level in the brain. Thus, T1-11 enters the brain and
elevates cAMP via activation of the A2AR in vivo. Most importantly, addition of T1-11 (0.05 mg/ml) to the drinking water of a
transgenic mouse model of HD (R6/2) ameliorated the progressive deterioration in motor coordination, reduced the
formation of striatal Htt aggregates, elevated proteasome activity, and increased the level of an important neurotrophic
factor (brain derived neurotrophic factor) in the brain. These results demonstrate the therapeutic potential of T1-11 for
treating HD.
Conclusions/Significance: The dual functions of T1-11 enable T1-11 to effectively activate the adenosinergic system and
subsequently delay the progression of HD. This is a novel therapeutic strategy for HD. Similar dual-function drugs aimed at a
particular neurotransmitter system as proposed herein may be applicable to other neurotransmitter systems (e.g., the
dopamine receptor/dopamine transporter and the serotonin receptor/serotonin transporter) and may facilitate the
development of new drugs for other neurodegenerative diseases.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disease characterized by chorea, dementia, and
psychiatric symptoms. As the disease progresses, concentration
and short-term memory diminish and involuntary movements of
the head, trunk, and limbs increase. Walking, speaking, and
swallowing abilities deteriorate. Eventually, death results from
complications such as choking, infection, or heart failure. The
causative mutation is a CAG trinucleotide expansion in exon 1 of
the Huntingtin gene (Htt) [1]. The normal Htt gene has 35 or
fewer CAG repeats in its N-terminal region, whereas that of HD
patients is associated with 36 or more repeats. The expanded CAG
repeats are translated into polyglutamine residues (polyQ) in the
Htt protein. When the number of CAG repeats exceeds 35,
degeneration of several brain areas (particularly the striatum)
occurs. Formation of Htt aggregates and alteration of overall gene
expression profiles have also been reported in peripheral tissues,
including blood cells, the liver, and the kidney [2,3]. Drugs
currently available for treating HD patients are mostly for
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20934symptom relief, and some have unfavorable side effects [4].
Effective treatments for HD are yet to be developed.
Adenosine is an important neuromodulator that links neuronal
activity with energy metabolism [5]. Conditions that drain energy
reserves or cause an energy imbalance, such as intensive exercise
and ischemia, elevate adenosine levels [6]. There are four
adenosine receptors (A1,A 2A,A 2B, and A3) and several adenosine
transporters. Because of their expression profiles and affinities
toward adenosine, the A1R and A2AR are believed to regulate
important physiological functions in the brain. In particular, the
A2AR has attracted attention as a potential drug target in HD
because it is highly prevalent in the striatum, where mutant Htt
causes early damage. In addition, evidence from various
laboratories has clearly shown that tonic activation of the A2AR
is required for the function of several important neurotrophic
factors (including brain-derived neurotrophic factor, fibroblast
growth factor, and glial cell line-derived neurotrophic factor) [7–
9]. A2A-related drugs therefore have been implicated in the
treatment of HD [10–16]. We previously reported that an A2A
agonist (CGS21680, CGS) significantly ameliorates several
symptoms of HD (viz, brain atrophy, striatal aggregates,
deteriorated motor coordination, and urea cycle deficiency) in a
transgenic mouse model of HD [12,13]. Nevertheless, certain
adverse effects of currently available A2A drugs (e.g., CGS) that
exhibit high A2AR affinity prevent their clinical application [17].
In the present study, we describe a novel agonist [N
6-(4-
hydroxybenzyl)adenine riboside (designated T1-11)] of the A2AR
that also inhibits the adenosine transporter, and which may be
used to treat HD without evident side effects because of its
moderate affinity to its target molecules.
T1-11 was originally purified from Gastrodia elata (GE), a
Chinese medicinal herb that has been used extensively in Asia for
at least 1500 years. It is traditionally used to treat headaches,
dizziness, limb numbness, and spasms, especially those of
convulsive illnesses such as epilepsy and tetanus. Because of its
efficacy in treating epileptic diseases, many studies have been
performed to investigate its role in preventing neuronal damage.
For example, gastrodin, a component of GE, was shown to alter
GABA metabolism in the gerbil hippocampus [18]. The ether
fraction of GE also significantly reduced neuronal cell death
induced by b-amyloid [19]. We previously reported that two active
components [T1-11 and bis(4-hydroxybenzyl)sulfide] purified
from an aqueous methanolic extract of GE prevented apoptosis
of serum-deprived PC12 cells by suppressing JNK activity [20,21].
Herein, we demonstrate that T1-11 protects PC12 cells in vitro and
also exerts a beneficial effect on symptom progression in a mouse
model of HD via targeting two components of the adenosinergic
mechanism.
Results
Purification of T1-11 from a Chinese herb
We previously reported that a fraction of GE prevents apoptosis
in PC12 cells by activating the A2AR [20]. In the present study, we
further purified the active component of this GE extract. The
aqueous ethanolic extract of GE (,15% yield based on dried
weight) was subjected to Diaion HP-20 column chromatography
using elution from H2O to MeOH gradients. As shown in
Figure 1A, several fractions of the aqueous methanolic extract
conferred protection against PC12 cell death induced by serum
withdrawal. The most effective dosage was the 75% MeOH
fraction, which was subjected to further fractionation and
purification using Sephadex LH-20 column chromatography
(Fig. 1B). Sixteen known compounds (including gastrodin, 4-
hydroxybenzaldehyde, and parishin) and one previously unchar-
acterized component (T1-11) were identified [22–24]. Of these
compounds, T1-11 was considered the most promising because it
is an adenosine analogue (Fig. 1B). HPLC was used to monitor the
chemical profiles of various batches based on their ability to
prevent cell death induced by serum withdrawal. Chromatograms
of the active fractions showed that the retention time for T1-11
was 22.03 min (Fig. 1B; Supplementary Figs. S1, S2). T1-11 is a
colorless amorphous powder with a molecular formula of
C17H20O5N5. Spectral methods (HR-FAB-MS, IR,
1H, and
13C
NMR) determined that the structure of T1-11 is N
6-(4-hydro-
xybenzyl)adenine riboside [21], which we subsequently confirmed
by synthesis (Supplementary Fig. S3). T1-11 constitutes about
0.3% of the 75% MeOH fraction of GE. To the best of our
knowledge, the clinical use of T1-11 has not previously been
investigated. In PC12 cells, T1-11 protected against serum
withdrawal-induced cell death in a dose-dependent manner
(Fig. 1C). Staining with annexin V-FITC confirmed that T1-11
rescued serum-deprived PC12 cells from apoptosis (Fig. 1D).
T1-11 is an agonist of the A2AR and an inhibitor of the
adenosine transporter
We further characterized the pharmacological properties of T1-
11 using radioligand binding assays. Of the 208 receptors/
transporters tested, 10 mM T1-11 bound to only three molecules of
the adenosinergic system including the A2AR, A3R, and an
adenosine transporter - equilibrative nucleoside transporter 1
(ENT1; Table 1, Supplementary Table S1). Of these molecules,
T1-11 bound to the A3R with the highest affinity (Ki=0.1 mM,
Table 1). However, at a concentration (100 mM) approximately
1000-fold higher than its Ki value, T1-11 induced less than 50%
GTP binding compared to a well-characterized A3 agonist (2-Cl-
IB-MECA, 3 mM, Supplementary Fig. S4). This low level of GTP
binding is considered insufficient to trigger the G protein-
dependent signaling of the A3R, suggesting that despite its strong
binding affinity, T1-11 may not be a functional ligand for the A3R.
In contrast, T1-11 appeared to activate the A2AR (Table 1). We
assessed the effect of two A2AR antagonists (ZM241385 and
SCH58216) on T1-11’s ability to prevent serum deprivation-
induced death in PC12 cells and found that treatment with either
antagonist blocked the effect of T1-11, indicating that T1-11’s
anti-apoptotic function is mediated at least in part by its role as a
ligand for the A2AR (Fig. 1E). Treatment of PC12 cells with T1-11
dose-dependently elevated the cellular cAMP levels (Fig. 2A), and
the EC50 value (,2.2 mM) was similar to its binding property
toward the A2AR (Table 1). The A2AR-selective antagonist
(SCH58216, SCH) effectively blocked the T1-11-induced eleva-
tion in the cAMP level (Fig. 2B), further supporting the hypothesis
that T1-11 activates a cAMP-dependent pathway by stimulating
A2AR. Importantly, a single intraperitoneal injection of T1-11
(5 mg/kg body weight) increased cAMP levels in the brains of
wildtype, but not A2AR knockout [25], mice (Fig. 2C). In addition,
T1-11 was detected in the brain 30 min after the intraperitoneal
injection (0.1260.01 ng/g brain lysate, n=4; mean 6 s.e.m.).
These data indicate that T1-11 enters the brain and elevates
cAMP via activation of the A2AR in vivo.
T1-11 also bound to an adenosine transporter ENT1 (Table 1,
Ki=0.54 mM). T1-11 inhibited adenosine uptake by PC12 cells in
a dose-dependent manner (Fig. 3A). The maximal inhibition of
adenosine transport evoked by T1-11 at a concentration of 30 mM
(,55-fold its Ki value, Table 1) was similar to that caused by a
well-characterized ENT1 inhibitor [nitrobenzylthioinosine, NBTI;
100 nM, 118-fold its Ki value (0.85 nM)] (Fig. 3B). Most
importantly, introduction of T1-11 into the striatum of wildtype
A Dual Function Drug for Huntington’s Disease
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20934Figure 1. A fraction of the GE extract prevents serum-deprived PC12 cell apoptosis. (A, C, E) Serum-deprived PC12 cells were treated with
or without the indicated reagent(s) for 24 h. Cell viability was expressed as a percentage of the MTT activity measured in the serum-containing group.
Data points represent the mean 6 s.e.m. of at least three independent experiments. *p,0.05, versus the corresponding serum-deprived group.
a p,0.05, versus the corresponding serum-deprived/T1-11 treated group. (B) Chromatogram of active fractions of GE conducted by HPLC on a Merck
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determined by microdialysis (Fig. 3C), demonstrating that T1-11
inhibited adenosine uptake in vivo. Thus, in addition to its ability to
activate the A2AR, administration of T1-11 increases adenosiner-
gic tone in vivo.
T1-11 binds to the adenosine pockets of the A2AR and of
the ENT1
We next analyzed whether T1-11 fits into the ligand binding
sites of activated A2AR (Fig. 4) and ENT1 (Fig. 5). From the newly
resolved structure of human A2AR bound to the antagonist,
ZM241385, in the inactive state [26] and previous mutagenesis
experiments [17,27], it was evident that the -NH2 interaction of
the adenine core in CGS has the same binding interaction motifs
as the antagonist, ZM241385 [26]. As shown in Figure 4A, the
predicted binding of CGS to the structural model of the activated
state of the human A2AR involves many hydrogen bonds with
residues Thr88 [27], Asn253 [28], Glu169 [29], Ser277 [28], and
His278 [30], which were identified by previous mutagenesis
experiments. T1-11 docked to the same A2AR structural model,
and was also involved in interactions with residues Asn253,
Ser277, and His278, but with fewer hydrogen bonds (Fig. 4B).
This analysis indicates that T1-11 fits into the ligand-binding site
of the A2AR with a weaker affinity than CGS.
Because of the lack of a suitable structural template for
homologous modeling of human ENT1 (hENT1), we conducted
threading-based ab inito modeling of this transporter. The
structural model of hENT1 resembles the structure of lactose
permease (GlpT) [31], even though the number of transmembrane
helices is different (11 for hENT1 vs. 12 for GlpT). This structure
was further refined by a molecular-dynamics simulation in the
fully solvated lipid bilayer, as detailed in ‘‘Materials and
Methods’’. Docking the well-known hENT1 inhibitor, NBTI,
and T1-11 to the refined structure generated the binding modes
depicted in Figure 5A and 5B, respectively. NBTI and T1-11
bound to the transporter in the substrate translocation channel
with similar orientations at similar binding sites.
Chronic treatment with T1-11 has beneficial effects on
several major symptoms of HD in a transgenic mouse
model of HD
As the A2AR and ENT1 are located in the striatum and have
been implicated in striatal function [32], we hypothesized that
chronic treatment with T1-11 would modulate the progression of
HD. We first tested the effect of T1-11 in a transgenic mouse
model (R6/2) of HD in which A2AR agonists have beneficial
effects [12,13]. The addition of T1-11 (0.05 mg/ml) to the
drinking water of mice from the age of 7 weeks counteracted the
progressive deterioration in motor coordination as assessed by
rotarod performance (Fig. 6A). The mean survival times of control
and T1-11-treated R6/2 mice were 99.062.1 d (n=22) and
103.363.9 d (n=11), respectively (Supplementary Fig. S5A).
Using in vivo 3D MRI imaging, we found that T1-11 slightly
ameliorated the brain atrophy of R6/2 mice but the improvement
did not reach statistic significance (Supplementary Fig. S5B).
Importantly, chronic treatment with T1-11 markedly reduced the
formation of striatal Htt aggregates, a hallmark of HD, as assessed
by filtered retardation assays (Fig. 6B) and immunofluorescence
analyses (Fig. 6C). We recently reported that activation of the
A2AR enhances mHtt-induced suppression of proteasome activity
via a PKA-dependent pathway in the liver [12]. Therefore, we
determined whether T1-11 decreases aggregate formation by
elevating proteasome activity. As shown in Figure 6D, chymo-
trypsin-like activity in the striatal synaptosome fractions was lower
in HD mice than in wildtype mice. Chronic treatment with T1-11
significantly enhanced chymotrypsin-like activity in the HD
striatum (Fig. 6D). We also assessed whether T1-11 modulates
other changes in brains of R6/2 mice. A previous study showed
that the level of brain derived neurotrophic factor (BDNF) was
decreased in the brains of HD mice [33]. Consistent with the
beneficial effects of T1-11 on motor coordination, we found that
T1-11-treated R6/2 mice contained more cortical BDNF than
R6/2 mice that received no treatment (Fig. 6E). These results
demonstrate the therapeutic potential of T1-11 for treating HD.
Discussion
We identified a novel adenosine analogue, T1-11, that possesses
a dual function - both activating adenosine receptors and blocking
the adenosine transporter ENT-1. Our data suggest that by
simultaneously activating the A2AR and inhibiting adenosine
uptake, T1-11 produces beneficial effects on HD by selectively
elevating the adenosinergic tone of the brain, a novel protective
mechanism.
Adenosine is an important endogenous neuroprotective sub-
stance and is a metabolite of many biosynthetic pathways. The
endogenous adenosine level is known to be associated with the
status of energy homeostasis in the brain [5]. Certain psycho-
pharmacological agents (e.g., caffeine and ethanol) function by
modulating the endogenous adenosine tone of the brain [34]. Our
finding that T1-11-mediated elevation of adenosine tone had
beneficial effects in R6/2 mice is consistent with a previous report
showing that an increase in the adenosine tone of the brain exerts
a protective effect on cerebral ischemia [35]. Modulation of the
adenosine tone by pharmacological means may be useful in
developing therapies for neurodegenerative diseases and/or
RP-18e (25064.6 mm) column. The position of T1-11 is indicated by an arrow. The structure of T1-11 is shown in the upper right corner. (D) Serum-
deprived PC12 cells were treated with serum or T1-11 (10 mM) as indicated for 24 h, stained with annexin V-FITC, and analyzed using microscope and
flow cytometry. The median values of FITC fluorescence intensities were collected using an FL-1 channel (bottom panel). Representative pictures of
cells in each condition are shown. Bars:10 mm. Data points represent the mean 6 s.e.m. of at least three independent experiments.
doi:10.1371/journal.pone.0020934.g001
Table 1. Pharmacological properties of T1-11.
Target Molecules IC50 (mM) Ki (mM) Function
A1 adenosine receptor n.s. n.s. n.d.
A2A adenosine receptor 4.66 2.62 agonist
A2B adenosine receptor n.s. n.s. n.d.
A3 adenosine receptor 0.11 0.10 n.s.
Adenosine transporter (ENT1) 1.57 0.54 inhibitor
Binding properties of T1-11 toward four adenosine receptors (A1,A 2A,A 2B,a n d
A3 receptors) and one adenosine transporter (ENT1) were conducted and
characterized using standard binding protocols. T1-11 is an agonist of the A2AR
to activate adenylyl cyclases and subsequently elevate cellular cAMP levels
(Fig. 2). T1-11 also suppressed the uptake of adenosine (Fig. 3), and therefore
was considered an inhibitor of ENT1. No significant binding of T1-11 toward the
A1Ro rA 2BRa t1 0mM was found. Although T1-11 also bound to the A3R, it
evoked no significant GTPcS binding at a concentration (10 mM) 1000-fold of its
1000-fold of its Ki value. n.d., not determined. n.s., not significant.
doi:10.1371/journal.pone.0020934.t001
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been developed. For example, propentofylline, a weak inhibitor of
three adenosine receptors (with a preference for the A1R) and
adenosine transporters, can be used to treat dementia and
ischemic brain damage [36]. The action of propentofylline is
intriguing and complex as it indirectly enhances functions of
adenosine receptors via inhibition of adenosine transporters which
elevate extracellular adenosine concentrations, and directly
suppresses adenosine receptors, limiting its former action [36].
Although the binding affinities of T1-11 were not as strong as
those of the best adenosine drugs currently available (Table 1,
Figs. 2, 3, 6), the dual functions of these compounds in activating
adenosine receptors and inhibiting adenosine transporters is likely
to enable T1-11 to effectively activate the adenosinergic system in
synapses where both adenosine receptors and transporters are
located.
Despite the significant interest in A2AR-related drugs for HD,
earlier studies using different mouse models of HD showed
complex and even conflicting conclusions on the neuroprotective
versus neurodegenerative roles of the A2AR in HD. We earlier
published a review in which we evaluated whether the A2ARi sa
feasible drug target for HD, and concluded that more studies are
needed to clarify the application of A2AR drugs to HD [37].
Because stimulation of the A2AR triggers glutamate release, it was
proposed that the presynaptic A2AR on the glutminergic terminals
would be harmful, while that on the postsynaptic GABAergic
Figure 2. T1-11 is an agonist of the A2AR. (A) PC12 cells were treated with T1-11 (closed circles) and CGS21680 (open circles) at the indicated
concentration for 20 min at room temperature (RT). (B) PC12 cells were stimulated with T1-11 (10 mM) in the absence or presence of an A2AR
antagonist (SCH, 1 mM) for 20 min at RT. (C) Wildtype and A2AR knockout (KO) mice were intraperitoneally administrated with T1-11 (5 mg/kg body
weight, n=4) or vehicle for 60 min to measure the cAMP level in the brain.
doi:10.1371/journal.pone.0020934.g002
Figure 3. T1-11 inhibited the uptake of adenosine. (A) Adenosine uptake by PC12 cells was analyzed in the presence of T1-11 at the indicated
concentration. (B) Adenosine uptake by PC12 cells was evaluated in the presence of T1-11 (30 mM) or NBTI (0.1 mM) as indicated for 10 min. (C) T1-11
(100 mM) was perfused throughout the dialysis probe. The collected perfusates were analyzed for striatal adenosine levels. Data points represent the
mean 6 s.e.m.. * p,0.05, compared to the basal level.
doi:10.1371/journal.pone.0020934.g003
A Dual Function Drug for Huntington’s Disease
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A2AR is closely linked to BDNF which is markedly impaired in
HD [7,33,38,39]. Activation of the A2AR enhances the signal of
BDNF by facilitating localization of its receptor (TrkB) in lipid
rafts through a cAMP/PKA-dependent pathway, transactivates
TrkB, and increases the synthesis of TrkB [40,41,42]. Stimulation
of the A2AR also facilitates the functions of other neurotrophic
factors [such as the glial cell line-derived neurotrophic factor
(GDNF) and fibroblast growth factor (FGF)]. These findings are
important because supplementation with BDNF, GDNF, or FGF
in HD mice all led to beneficial effects on disease progression
[43,44]. Small molecules which activate the A2AR thus might
provide a unique means to elicit trophic responses in HD. It is
important to note that the expression and signaling of the A2ARa s
well as other receptors (e.g., D2 dopamine receptor and
metabotropic glutamate receptor) are altered in both HD mice
and patients [13,45–49]. The roles of the A2AR revealed by studies
conducted in wildtype animals therefore need to be re-evaluated in
genetic models of HD. Indeed, studies from several laboratories
showed that activation of the A2AR produces opposite effects in the
striatum of WT and HD (R6/2) mice [11,50]. In R6/2 mice,
treatment with an A2AR antagonist (SCH58261) for 1 week
worsened motor coordination [51]. Genetic removal of the A2AR
in another HD mouse model (N171-82Q) also exacerbated motor
Figure 5. Interactions of inhibitors with ligand binding sites of ENT1. (A) The binding pose of NBTI (a selective inhibitor of ENT1) on human
ENT1, as predicted using threading-based ab inito modeling of this transporter. The three-dimensional structure of ENT1 was constructed based on
the lactose permease (GlpT) structure. (B) Similar to (A), the binding pose of T1-11 on human ENT1.
doi:10.1371/journal.pone.0020934.g005
Figure 4. Interactions of the agonists with the ligand binding sites of the A2AR. (A) The binding pose of CGS21680 (a selective agonist) on
the human A2AR, as predicted by combined homology modeling and docking analysis. The three-dimensional structure of the activated-state A2AR
was constructed based on the inactive-state structure of the A2AR and the opsin structure. (B) Similar to (A), the binding pose of T1-11 on the human
A2AR.
doi:10.1371/journal.pone.0020934.g004
A Dual Function Drug for Huntington’s Disease
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20934Figure 6. T1-11 exhibited beneficial effects in a mouse model of HD. R6/2 mice were given the vehicle (1% DMSO; CON, n=53) or T1-11
(0.05 mg/ml, n=27)-containing drinking water from the age of 7 weeks. (A) Rotarod performance was conducted as described in ‘‘Methods’’. (B)
Striatal lysates (50,100 mg) collected from the indicated mice at the age of 12 weeks old were subjected to a filter retardation assay. The insoluble
Htt aggregates retained on the filter were detected using an anti-Htt antibody (upper panel). The amount of protein in each corresponding lysate was
independently assessed by Western blot analyses using an anti-actin antibody (middle panel). The relative aggregate formation was quantified by
A Dual Function Drug for Huntington’s Disease
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abovementioned 1-week treatment with SCH58261 in the
presymptomatic stage of R6/2 mice was associated with a
reduction in NMDA-induced toxicity, indicating a potential
protective effect [51]. Because the glutamate release was
dynamically altered from an enhancement at the presymptomatic
stage to a decrease at the symptomatic stage during disease
progression of HD mice [49], and since local glutamate level was
recently shown to dictate the effect of A2AR on neuronal death in
an animal model of traumatic brain injury [52], it is possible that
the stage of disease progression might contribute to the complex
role of A2AR in HD. Further investigations using both pharma-
cological and genetic approaches are necessary to verify whether
early and/or chronic blockage of the A2AR is detrimental during
HD progression. Conversely, activation of the A2AR using CGS
provides beneficial effects on several major HD symptoms
(including brain atrophy, striatal aggregates, and deteriorated
motor coordination) in R6/2 mice [12,13]. In line with our
studies, Cepeda and colleagues also demonstrated that CGS
ameliorates the corticostriatal synaptic disconnection in R6/2
mice [11]. Agonists of the A2AR therefore might be used to treat
HD. Unfortunately, full A2A agonists (e.g., CGS) have unfavorable
acute side effects, including low food intake, sedation/drowsiness,
an increased heart rate, and systematic hypotension [17,53,54]. A
modest agonist such as T1-11 may have fewer side effects in
peripheral tissues and may thus be superior to full A2A agonists for
therapeutic uses such as those of other classes of adenosine drugs
[55]. We tested this hypothesis by treating R6/2 mice with T1-11
using a subcutaneous Alzet minipump for 48 h. At a dose that
improved motor deterioration, T1-11 did not change the blood
pressure of R6/2 mice (Supplementary Materials, Figure S6). The
rapid entry of T1-11 into the brain suggests that it may have great
potential for treating brain diseases. Collectively, T1-11 possesses
key features of an ideal A2A drug for HD. In the present study, T1-
11 was delivered via the drinking water because it is one of the
most common routes for drug delivery in human patients and it
causes much less stress on mice than intraperitoneal injection or
oral gavage. Nonetheless, such mode of drug delivery did not
permit an accurate assessment of the actual doses taken by the
animals. In addition, HD mice at late stage of the disease drink less
water because of impaired motor function, and thus receive less
T1-11. Such reduced intake of T1-11 by mice with late stage HD
might compromise the beneficial effect of T1-11 and account for
the inability of T1-11 to rescue certain symptoms of HD (e.g.,
shorten lifespan and brain atrophy, Supplementary Figure S5). For
potential clinical application of T1-11 in the future, it is critical to
further optimize its effective dose, formulation, and administration
protocol to maximize its beneficial effect.
The protective effects of the GE extract and T1-11 are
consistent with a previously implied neuroprotective effect of GE
[18,19]. By targeting multiple components in the adenosinergic
system, T1-11 is expected to elevate the adenosine tone and is a
potential candidate for treating HD. In addition to the role of the
A2AR as discussed above, the functions of other adenosine
receptors (particularly, the A1R and A3R) in HD also warrant
further studies. In an earlier report, an A1R-specific agonist
(adenosine amine congener) showed neuroprotective effects in a
rat HD model created by the systemic administration of 3-
nitropropionic acid which caused striatal lesions [56]. The
functions of the A3R have not been evaluated in HD before.
Nonetheless, agonists of the A3R provide neuroprotective effects
against subarachnoid hemorrhage-induced brain damage [57].
The contributions of the A1R and A3R to the beneficial effects of
T1-11 on HD mice require further experimental evaluation.
The concept of a small molecule that targets multiple
components in the same regulatory system to optimize its function
at a specific location (such as synapses) is a novel strategy for
developing therapeutic methods for HD, for which there is
currently no effective treatment [58]. This approach is particularly
critical for the design of neurotransmitter-based drugs for CNS
diseases in which side effects from peripheral tissues are a major
obstacle. Dual-action drugs have recently attracted much attention
[59]. A drug (tapentadol) recently approved by the US FDA, also a
dual-action molecule, acts on molecules of two different neuro-
transmitter systems (a m-opioid receptor agonist and a norepi-
nephrine transporter) [60]. Another interesting example is 8-(3-
chlorostyryl)caffeine, a well-characterized A2A-selective antagonist
which ameliorates MPTP neurotoxicity by simultaneously inhib-
iting monoamine oxidase and the A2AR [61]. A similar design as
for dual-function drugs may be applicable to other neurotrans-
mitter systems (e.g., dopamine receptor/transporter and serotonin
receptor/transporter) and may facilitate the development of new
drugs for other neurodegenerative diseases.
Materials and Methods
Preparation of the GE extract and T1-11
The rhizome of G. elata (GE) was purchased from a local herbal
store in Taipei. Slices of GE were extracted at 60uC using 80%
ethanol/H2O overnight (3 times). The crude extract was
concentrated using a vacuum rotary evaporator (Bu ¨chi) under
reduced pressure. The dried sample (about 15% yield based on the
dried herbal weight) was subjected to Diaion HP-20 column
chromatography using elution from a H2O/MeOH gradient.
Fractions were examined for their abilities to prevent apoptosis
induced by serum withdrawal in PC12 cells. The active fractions of
50%,75% MeOH/H2O were combined and purified on a
Sephadex LH-20 column by repeated elution with MeOH to give
T1-11. High-pressure liquid chromatography was performed on a
Merck RP-18e (25064.6 mm) column using a mobile phase
gradient from 70% to 40% H2O/MeOH for 40 min and from
40% to 20% H2O/MeOH for 5 min at a flow rate of 0.8 ml/min.
A UV 270-nm detector was used to monitor the chemical profiles
of different batches.
Synthesis of T1-11
Compound T1-11 was synthesized in a high yield by the
substitution reaction of 6-chloropurine ribonucleoside with 4-
hydroxybenzylamine (as hydrochloric acid) in the presence of a
base diisopropylethylamine [62,63]. Because the hydrochloric salt
dividing the Htt signals in filter assays with those of the corresponding actin signals in Western blots (bottom panel). Data are presented as the mean
6 s.e.m. values from three independent experiments. * p,0.05, versus R6/2 mice with no treatment (CON, Student’s t test). (C) Brain sections of 12-
week-old animals [vehicle (CON)-treated WT mice (n=5), vehicle-treated R6/2 mice (n=5), and T1-11-treated R6/2 mice (n=5)] were stained with an
anti-Htt antibody. Mutant Htt aggregates were visualized using Alexa Flour 568 (red). Nuclei were visualized using H33258 (blue). Representative
pictures are shown. The scale bar is 10 mm. Data are presented as the mean 6 SEM in each group. *** p,0.001, versus R6/2 mice treated with vehicle
(CON, Student’s t test). (D) The chymotrypsin-like activity of proteasomes in striatal synaptosomes of the indicated 12-week-old mice (n=3) was
assessed as described in ‘‘Methods’’. (E) Cortical tissues (n=3) were collected to determine the transcript level of BDNF using a quantitative RT-PCR
technique. The expression levels of BDNF were normalized to that of GAPDH. * P,0.05, versus R6/2 mice with no treatment (CON, Student’s t test).
doi:10.1371/journal.pone.0020934.g006
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prepared by hydrogenation of the corresponding 4-hydroxyben-
zaldehyde oxime.
Cell culture
PC12 cells purchased from ATCC (Manassas, VA, USA) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% horse serum and 5% fetal bovine serum
and incubated in a CO2 incubator (5%) at 37uC.
MTT metabolism assay
Survival was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) metabolism assay as de-
scribed elsewhere [64,65]. In brief, cells grown on 150-mm plates
were washed three times with PBS and resuspended in DMEM.
Suspended cells (1610
4 cells) were plated on 96-well plates and
treated with or without the indicated reagent. After incubation for
24 h, MTT (0.5 mg/ml) was added to the medium and incubated
for 3 h. After discarding the medium, DMSO (100 ml) was then
applied to the well to dissolve the formazan crystals derived from
the mitochondrial cleavage of the tetrazolium ring by live cells.
The absorbance at 570/630 nm in each well was measured on a
micro-enzyme-linked immunosorbent assay reader.
Annexin V-FITC staining
An annexin V (FITC-conjugated) apoptosis kit (K101-400;
BioVision, Mountain View, CA, USA) was used to analyze
apoptotic cells. The experimental protocol followed the manufac-
turer’s instructions and a previous article [66]. In brief, after
treatment with serum, serum-free medium, or serum-free medium
plus T1-11 of the indicated concentration for 24 h, cells growing
on 12-well plates at (3,4)610
5 cells/well were loaded with 0.5 ml
binding buffer and 5 ml annexin V-FITC. After incubation for
5 min in the dark, cells were washed once with 1 ml of culture
medium (without phenol red) for fluorescent imaging analyses
(Axiovert-200M, Carl Zeiss, Go ˆttingen, Germany) or a flow
cytometric analysis (Beckton Dickinson, Franklin Lakes, NJ, USA).
Median values of the FITC fluorescent intensities were determined
using an FL-1 channel (488/530Ex/Em nm). Five thousand live
cells were analyzed per sample.
Radioligand binding assays
Radoligand binding assays were performed by MDS Pharma
Services Taiwan (Taipei, Taiwan) using standard binding
protocols. For the binding assay of the A2AR [67], membrane
proteins collected from HEK293 cells overexpressing the human
A2AR were incubated in reaction buffer [50 mM Tris-HCl
(pH 7.4), 10 mM MgCl2, 1 mM EDTA, and 2 U/mL adenosine
deaminase] containing
3H-CGS21680 (50 nM) for 90 min at
25uC. Nonspecific binding was assessed in the presence of
50 mM adenosine- 59-N-ethylcarboxamide. To measure the
binding affinity of T1-11 to the A3R [68,69], membrane
proteins collected from CHO-K1 cells overexpressing the
human A3R were incubated with
3H-AB-MECA (0.5 nM) for
60 min at 25uC in a reaction buffer containing 25 mM HEPES
(pH 7.4), 5 mM MgC2, 1 mM CaCl., and 0.1% bovine serum
albumin. Nonspecific binding was assessed in the presence of
1 mM IB-MECA (Tocris Bioscience, Ellisville, MS, USA).
Binding assays for adenosine transporters were conducted as
described earlier ([70]. Membrane fractions collected from the
cerebral cortex of Duncan Hartley derived guinea pigs were
incubated with
3H-labeled 6-[(4-nitrobenzyl)thio]-9-b-D-ribofur-
anosylpurine (NBTI, 0.5 nM) for 30 min at 25uCi na n
incubation buffer containing 50 mM Tris-HCl (pH 7.4). Non-
specific binding was assessed in the presence of 5 mMN B T I ,a n
effective inhibitor of equilibrative nucleoside transporters. Note
that NBTI is a high-affinity inhibitor of ENT1, and inhibits only
human (h)ENT1 at 0.5 nM [71]. Reactions were terminated by
filtration over GF/B glass fibers and washing with the
corresponding reaction buffer.
cAMP assay
PC12 cells were plated at the density of 5610
5 cells/well (on 12-
well plates) and incubated with the indicated reagent(s) for the
desired period of time. Cells were washed twice with ice-cold
Locke’s solution (150 mM NaCl, 5.6 mM KCl, 5 mM glucose,
1 mM MgCl2, and 10 mM HEPES, adjusted to pH 7.4). Cellular
cAMP was extracted by adding 0.3 ml of 0.1 M HCl to each well
and incubating this for 10 min on ice. The cAMP content was
assayed using the
125I-cAMP assay system (GE Healthcare, Little
Chalfont, Buckinghamshire, UK).
C57BL6 mice (8 weeks old) were intraperitoneally (i.p.)
administrated with T1-11 (5 mg/kg body weight, n=4) or vehicle
for 60 min. Brain tissues were carefully removed, and homoge-
nized in 1 ml of assay buffer (25 mM Tris (pH 8), 1 mM EGTA,
1 mM MgCl2, 40 mM leupeptin, 100 mM PMSF, 10 nM okadaic
acid, 16EDTA free proteinase inhibitor cocktail (Roche), 0.5 mM
IBMX, and 20 mM papaverine). Trichloroacetic acid (6%, final
concentration) was then added to the lysate to precipitate proteins.
The cAMP level in the supernatant was analyzed as previously
described.
GTPcS binding assay
The GTPcS binding assay was conducted by MDS Pharma
Services Taiwan using a previously described protocol [55] with
slight modifications. In brief, membrane proteins collected from
Chinese hamster ovary (CHO-K1) cells expressing the human
A3R( 5 ,10 mg per reaction) were incubated with the indicated
drug and
35S-GTPcS (0.1 nM) in a total volume of 500 ml for
30 min at 30uC. The reaction buffer was composed of 20 mM
HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 1 mM DTT,
and 1 mM EDTA. The reaction was terminated by filtration over
GF/B glass fibers and washed with the same reaction buffer.
Relative GTPcS binding was defined as the percentage of
35S-
GTPcS binding when compared to that of a selective agonist of
the A3R (2-Cl-IB-MECA, 3 mM) under the same binding
conditions.
Adenosine transport
For adenosine uptake of PC12, cells were seeded approximately
16 h before each uptake assay at ,2610
5 cells per well in 24-well
plates coated with poly-L-lysine. To perform adenosine uptake
assays, cells were washed with Krebs Ringer-Henseleit buffer
[125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4,
1.2 mM KH2PO4, 5.6 mM glucose, 10 mM pargyline, and
10 mM HEPES (pH 7.2)] and incubated in the same buffer for
10 min at 37uC in the presence or absence of the indicated
reagent(s). Adenosine uptake was initiated by adding [
3H]adeno-
sine at the indicated concentration (0.5 mCi/mmol) at 37uC. At
the end of the incubation, cells were placed on ice, washed twice
with ice-cold Krebs Ringer-Henseleit buffer to remove free
[
3H]adenosine, lysed with 1% Triton X-100, and added to
scintillation vials to count the radioactivity. Non-specific uptake
was determined as the uptake performed in the presence of
100 mM adenosine, and was subtracted from the total adenosine
uptake.
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The level of adenosine in the brain was determined using
microdialysis as previously described [72,73]. In brief, concen-
trated dialysis probes with 4-mm dialysis membranes (CMA,
Stockholm, Sweden) were used to monitor the extracellular
adenosine in the striatum of rats. After inducing anesthesia with
chloral hydrate (400 mg/ml, IP), rats were implanted with the
probe, and the coordinates for implantation were AP +1.0 mm,
LM +2.8 mm, and VD 26.5 mm. Ringer’s solution (140 mM
NaCl, 1.2 mM CaCl2, 3.0 mM KCl, 1.0 mM MgCl2, and
0.04 mM ascorbic acid) was continuously perfused (0.5 ml/min)
via probes throughout the experiments. After implantation and
perfusion for 1.5 h, the perfusate was collected for 1 h as a
baseline and then Ringer’s solution containing T1-11 (100 mM)
was perfused for another 1 h. The perfusate was analyzed by high-
performance liquid chromatography (HPLC; Agilent 1100 series,
Germany) coupled with a photo diode array detector (Agilent
G1315B,) at 260 nm. Separations were obtained with a reversed-
phase column (Cosmosil 5C18-AR-II, 25064.6 mm, Kyoto,
Japan) eluted at a flow rate of 1.0 ml/min with a linear solvent
gradient elution system composed of eluents A and B (A: 0.0085%
H3PO4 in H2O; B: 100% acetonitrile) according to the following
profile: 0,15 min, 100%,90% A, 0%,10% B.
Animals and drug administration
Male R6/2 mice [74] and littermate controls were originally
obtained from Jackson Laboratories (Bar Harbor, ME, USA), and
mated to female control mice (B6CBAFI/J). Offspring were
identified by a polymerase chain reaction (PCR) genotyping
technique of genomic DNA extracted from tail tissues using
primers located in the transgene (59-CCGCTCAGGTTCT-
GCTTTTA-39 and 59-GGCTGAGGAAGCTG- AGGAG-39)t o
ensure that the number of CAG repeats remained approximately
150. In total, 211 R6/2 transgenic mice were used in this study.
Animals were housed at the Institute of Biomedical Sciences
Animal Care Facility under a 12-h light/dark cycle. Body weights
of mice were recorded once daily. Animal experiments were
performed under protocols approved by the Academia Sinica
Institutional Animal Care and Utilization Committee, Taipei,
Taiwan.
Rotarod performance
Motor coordination was assessed using a rotarod apparatus
(UGO BASILE, Comerio, Italy) at a constant speed (12 rpm) over
the period of 2 min [75]. All mice were trained for 2 days at the
age of 4 weeks to allow them to become acquainted with the
rotarod apparatus. Animals were then tested three times per week
from the ages of 4,12 weeks. For each test, animals were placed
in the apparatus before initiation of rotation. Latency to falling was
automatically recorded. Each mouse was given three trials for a
maximum of 2 min for each trial.
Hemodynamic Examination
Heart rates and blood pressure of conscious and anesthetized
mice were measured using a blood pressure monitor (model MK-
2000; Muromachi Kikai, Tokyo, Japan) between 10 AM to 6 PM.
Values of 12–18 successful readings per mouse were used to
determine the blood pressure.
Filter retardation assay
SDS-insoluble mutant Htt aggregates were detected and
quantified as described [76]. A filter retardation assay was
performed as described previously [2]. Blots were blocked with
5% skim milk in phosphate-buffered saline (PBS) and incubated
with an anti-Htt antibody (EM48, 1:500; Chemicon International,
Temecula, CA, USA) at 4uC overnight followed by the
corresponding secondary antibody for 1 h at room temperature.
Immunoreactive bands were detected by enhanced chemilumi-
nescence (Pierce) and recorded using Kodak XAR-5 film.
Immunohistochemistry and quantitation
Coronal serial sections (20 mm) containing the striatum
(interaural 5.34 mm/bregma 1.54 mm to interaural 3.7 mm/
bregma 20.1 mm) were immunohistochemically stained as
described previously [77]. Brain sections were blocked with
normal goat serum and incubated overnight with an anti-Htt
antibody (EM48, 1:500) at 4uC, followed by a 2 h-incubation with
a goat anti-mouse IgG conjugated to Alexa FluorH 568 at room
temperature. The nuclei were stained with Hoechst 33258. The
patterns of immunostaining were analyzed with a laser confocal
microscope (LSM510, Carl Zeiss MicroImaging Inc, Germany).
Five different brain sections of each animal were analyzed. At least
2000 cells from each animal were used to quantify the sizes of
mHtt aggregates using ImageJ software (http://rsbweb.nih.gov/
ij/; Research Services Branch of the National Institute of Mental
Health, Bethesda, MD, USA).
Proteasome activity assay
The chymotrypsin-like activity of the proteasome was deter-
mined using a specific proteasome substrate [succinyl (suc)-Leu-
Leu-Val-Tyr-7-amino-4-methyl coumarin (AMC)] (Sigma-Al-
drich, St Louis, MO, USA) as described earlier [12]. In brief,
the synaptosome-enriched fraction (10 mg) were incubated with
the substrate (40 mM) in 100 ml of proteasome assay buffer
[0.05 M Tris-HCl (pH 8.0), 0.5 mM EDTA, 1 mM ATP, and
1 mM DTT] at 37uC for 60 min where the relationship between
the incubation time and product formation remained linear. The
fluorescence of the released AMC was detected using a
Fluorescence Microplate Reader System (Device, Sunnyvale,
CA, USA) at 380-nm excitation and 460-nm emission wave-
lengths.
Western blot assays
Equal amounts of protein were separated by sodium dodecyl-
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 10%
polyacrylamide gels according to the method of Laemmli [78].
The resolved proteins were electroblotted onto Immobilon
polyvinylidene difluoride membranes (Millipore, Bedford, MA,
USA). Membranes were blocked with 5% skim milk in PBS and
incubated with an anti-actin antibody (1:2500; Chemicon
International) at 4uC overnight followed by the corresponding
secondary antibody for 1 h at room temperature. Immunoreactive
bands were detected by enhanced chemiluminescence (Pierce) and
recorded using Kodak XAR-5 film.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from the cortex of the indicated mice
using the TriReagent kit (Molecular Research Center, Cincinnati,
OH, USA), treated with RNase-free DNase (RQ1; Promega) to
remove potential contamination by genomic DNA, and tran-
scribed into complementary (c)DNA using Superscript* II reverse
transcriptase. A real-time quantitative PCR was performed using a
TaqMan kit (PE Applied Biosystems, Foster City, CA, USA) on a
TaqMan ABI 7700 Sequence Detection System (PE Applied
Biosystems) using heat-activated TaqDNA polymerase (Amplitaq
Gold; PE Applied Biosystems). The PCR mixtures were incubated
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were conducted (95uC for 15 s and 65uC for 1 min). The
sequences of primers are listed below: for BDNF (the target gene),
59-GGCTTCACAGGAGACATCAG-39 and 59-CAGAACCA-
GAACGAACAGAAAC-39; and for GAPDH (the reference gene),
59TATCCGTTGTGGATCTGACAT-39 and 59-ACAACCTG-
GTCCTCAGTGTA-39. Independent reverse-transcription PCRs
were performed using the same cDNA for both the indicated
target gene and reference gene (GAPDH). A melting curve was
created at the end of the PCR cycle to confirm that a single
product had been amplified. Data were analyzed using ABI 7700
operating software to determine the threshold cycle (CT) above
the background for each reaction. The relative transcript amount
of the target gene, which was calculated using standard curves of
serial RNA dilutions, was normalized to that of GAPDH of the
same RNA.
Structure modeling of the activated human adenosine
A2A receptor
Multiple sequence alignment was performed with ClustalW [79]
for bovine rhodopsin, and the human adenosine A1,A 2A,A 2B, and
A3 receptors, where the BLOSUM scoring matrix, a gap open
penalty of 10, and a gap extension penalty of 0.05 were used.
Sequences were retrieved from Swiss-Prot [80]. To model the
active state of the human adenosine A2AR (residues 1,310),
residues 1,172 (except for the unresolved residues, 1 and 2, and
148,156) were taken from the recently solved inactivated
structure (PDB ID: 3EML) [26], because it was found that these
residues probably remained intact during the transition between
the active and inactive states [81]. The extracellular loop 2, which
should contribute to the binding of ligands to the receptor, is
therefore based on the inactive structure of the A2AR. The
unsolved residues, 1 and 2 and 148,156 were patched with the
program loopy [82]. TM5, TM6, TM7, and helix 8, i.e., residues
175,310, were modeled based on the opsin structure [81].
MODELLER9v5 [83] was used for the chimerical modeling, and
100 models were generated. Finally, the model with the lowest
DOPE energy [84] was selected. The hydrogen atoms were added
by the PDB2PQR web server [85] at pH 7, but the Nd atom of
His278 was manually assigned to be protonated and the Ne atom
was not protonated, because the binding mode of this protonation
assignment would be in better agreement with the mutation
experiment. During the revision of the manuscript, the structure of
A2AR bound with the agonist UK-432097 has been published
[86]. We compared the model we constructed in this work with the
newly released structure and found that these two structures are
very similar, especially at the binding pocket of the receptor.
Structure modeling of hENT1
The sequence of hENT1 was retrieved from Swiss-Port [80].
The initial models of hENT1 were constructed by iTASSER [87],
which is the iterative implementation of the Threading ASSEmbly
Refinement (TASSER) program [88]. One model was selected
based on the spatial distribution of the transmembrane regions
annotated by Swiss-Prot, to see whether the all the transmembrane
helices can be packed into the hydrophobic slab of a membrane.
All other models generated by iTASSER failed to meet this
criterion. This hENT1 model was inserted into the POPC bilayer
equilibrated in a previous study [89], where all the lipids and water
molecules having van der Waals contacts with the transporter were
removed. The system was energy-minimized by the steepest
descent method for 500 cycles, with all transporter atoms
restrained. The system was then equilibrated by conventional
molecular dynamics at 300 K and 1 bar for 1 ns. The self-guided
molecular dynamics simulation [90] was then conducted for 40 ns
to refine the hENT1 structure. The lipid force field parameters
were adopted from a previous study [89], and the AMBER
parm99SB force field [91] was used for the transporter. The
sander module of AMBER 9 [92] was employed for the
simulations.
Docking protocols
The partial charges of atoms on the ligand and the receptor
molecules were determined by the Gasteiger method [93], aided
by AutoDockTools. The number of chromosomes was set to 100,
and the number of generations was set to 5000. The Solis-Wet
local search iteration was set to 600. The binding pose of
CGS21680 was predicted with the program AutoDock 4 [94].
Supporting Information
Figure S1
1H NMR spectrum of T1-11 (DMSO-d6,
400 MHz).
(TIF)
Figure S2
13C NMR spectrum of T1-11 (DMSO-d6,
100 MHz).
(TIF)
Figure S3 HPLC diagram of a synthetic sample of T1-
11.
(TIF)
Figure S4 T1-11 binds to the A3 adenosine receptor
(A3R) without evoking a significant binding of GTP.
Membrane fractions collected from CHO-K1 cells expressing the
human A3R were incubated with T1-11 at the indicated
concentration and
35S-GTPcS (0.1 nM) for 30 min at 30uC.
Relative GTPcS binding was defined as the percentage of
35S-
GTPcS binding when compared with a selective agonist of the
A3R (2-Cl-IB-MECA, 3 mM).
(TIF)
Figure S5 Effect of T1-11 on the shorten lifespan and
enlarged ventricle of R6/2 mice. Animals were given the
vehicle (1% DMSO; CON) or T1-11 (0.05 mg/ml)-containing
drinking water from the age of 7 weeks. (A) Survival was assessed.
Specific comparison to R6/2 mice treated with the vehicle
(p=0.306; Mantel-Cox test). (B) Five weeks after T1-11 treatment,
3D-lMRI was performed to determine the ventricle-to-brain ratio
of the indicated animals as described. * p,0.05.
(TIF)
Figure S6 Treatment of R6/2 mice with T1-11 did not
affect their heart rate and blood pressure. (A) T1-11
(125 mg/mouse/day) or vehicle (CON) was administrated subcu-
taneously to the indicated mice of 7 weeks old using ALZET
osmotic minipumps for 6 weeks. Rotarod performance was
assessed. (B, C) T1-11 (125 mg/mouse/day) was administrated
subcutaneously to the indicated mice of 9 weeks old using ALZET
osmotic minipumps for 48 h. Heart rate (B) and blood pressure (C)
were determined by a tail-cuff method. * p,0.05. *** p,0.005.
(TIF)
Table S1 Binding properties of T1-11 toward 208 proteins.
(PDF)
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